UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 27, 2010
ALIMERA SCIENCES, INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| |
|
|
|
| 001-34703
|
|
20-0028718 |
| (Commission File No.)
|
|
(IRS Employer Identification No.) |
6120 Windward Parkway
Suite 290
Alpharetta, Georgia 30005
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (678) 990-5740
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure
Alimera Sciences, Inc. (the “Company”) issued a press release on May 27, 2010 regarding a
presentation that the Company will make at the Citi Health Care Conference in New York, New York on
Thursday, May 27, 2010. The full text of the press release is furnished as Exhibit 99.1 to this
Form 8-K and the slides that the Company will use for such presentation will be posted on the
Company’s website http://www.alimerasciences.com.
Various statements to be made in the presentation, including statements in the slides that
will be presented, are “forward-looking statements,” within the meaning of the Private Securities
Litigation Reform Act of 1995, regarding, among other things, the Company’s future results of
operations and financial position, business strategy and plans and objectives of management for the
Company’s future operations. The events and circumstances reflected in the Company’s
forward-looking statements may not occur and actual results could differ materially from those
projected in the Company’s forward-looking statements. Meaningful factors which could cause actual
results to differ include, but are not limited to, delay in or failure to obtain regulatory
approval of the Company’s product candidates, uncertainty as to the Company’s ability to
commercialize, and market acceptance of, the Company’s product candidates, the extent of government
regulations, uncertainty as to relationship between the benefits of the Company’s product
candidates and the risks of their side-effect profiles, dependence on third-party manufacturers to
manufacture the Company’s product candidates in sufficient quantities and quality, uncertainty of
clinical trial results, limited sales and marketing infrastructure, as well as other factors
discussed in the Company’s Securities and Exchange Commission filings, including the Company’s
final prospectus filed under Rule 424(b)(4) with the Securities and Exchange Commission in
connection with the Company’s initial public offering.
All forward-looking statements made in the presentation, including those in the slides that
will be presented, are expressly qualified by the above paragraph in their entirety. These
forward-looking statements speak only as of the date of the presentation (unless another date is
indicated). The Company undertakes no obligation, and specifically declines any obligation, to
publicly update or revise any forward-looking statements which are made in this presentation,
whether as a result of new information, future events or otherwise.
The information in Item 7.01 of this Form 8-K and the press release attached as Exhibit 99.1
to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by specific reference in such a filing.